ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Purchased by PFG Investments LLC

PFG Investments LLC increased its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 678.1% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 334,600 shares of the biotechnology company's stock after buying an additional 291,600 shares during the quarter. PFG Investments LLC owned about 0.15% of ADMA Biologics worth $2,208,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in ADMA. Allspring Global Investments Holdings LLC grew its position in ADMA Biologics by 3.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 252,602 shares of the biotechnology company's stock worth $1,667,000 after purchasing an additional 7,463 shares during the last quarter. Viewpoint Capital Management LLC boosted its stake in shares of ADMA Biologics by 18.6% during the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company's stock worth $102,000 after buying an additional 2,416 shares during the period. EWG Elevate Inc. grew its holdings in shares of ADMA Biologics by 100.0% during the first quarter. EWG Elevate Inc. now owns 100,000 shares of the biotechnology company's stock worth $660,000 after buying an additional 50,000 shares during the last quarter. Prism Advisors Inc. acquired a new position in ADMA Biologics in the 1st quarter valued at about $128,000. Finally, Stonepine Capital Management LLC raised its stake in ADMA Biologics by 1.3% during the 4th quarter. Stonepine Capital Management LLC now owns 9,222,617 shares of the biotechnology company's stock valued at $41,686,000 after acquiring an additional 118,342 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

Analyst Ratings Changes

ADMA has been the topic of a number of recent research reports. Mizuho boosted their target price on ADMA Biologics from $9.00 to $10.00 and gave the company a "buy" rating in a report on Friday, March 1st. Cantor Fitzgerald boosted their price objective on shares of ADMA Biologics from $6.50 to $8.00 and gave the company an "overweight" rating in a research note on Thursday, February 29th. Finally, HC Wainwright restated a "buy" rating and set a $7.50 price objective (up previously from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $7.88.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA traded up $0.11 during trading on Friday, hitting $6.55. 1,565,517 shares of the company were exchanged, compared to its average volume of 2,000,278. The firm's fifty day moving average price is $6.07 and its 200 day moving average price is $4.89. The company has a debt-to-equity ratio of 1.04, a current ratio of 5.16 and a quick ratio of 1.69. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -50.38 and a beta of 0.46. ADMA Biologics, Inc. has a 1 year low of $3.06 and a 1 year high of $6.76.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.02. ADMA Biologics had a negative net margin of 10.94% and a positive return on equity of 0.49%. The company had revenue of $73.90 million for the quarter, compared to analyst estimates of $73.50 million. On average, sell-side analysts expect that ADMA Biologics, Inc. will post 0.3 earnings per share for the current fiscal year.

Insider Activity

In other ADMA Biologics news, Director Steve Elms sold 407,000 shares of the firm's stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $6.21, for a total transaction of $2,527,470.00. Following the completion of the transaction, the director now directly owns 3,208,671 shares in the company, valued at approximately $19,925,846.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 639,895 shares of company stock worth $3,927,169 over the last 90 days. 6.00% of the stock is currently owned by corporate insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.